IRadimed Corporation IRMD

IRadimed is a high‑quality niche med‑tech: it dominates MRI‑room infusion with products hospitals actually need, throws off strong free cash flow, and posts excellent returns on capital. A newly cleared pump with higher pricing and easier use sets up a visible replacement wave that can feed recurring consumables and widen the moat. The catch is price and concentration—most of the value rests on smooth 2026 execution in a narrow market, while the stock already embeds a lot of success. As a business, it looks like a capable small compounder; as an investment, the quality premium is rich and leaves little room for missteps.